XML 56 R41.htm IDEA: XBRL DOCUMENT v3.3.1.900
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)
12 Months Ended
Jul. 02, 2015
USD ($)
Dec. 31, 2015
USD ($)
segment
reporting_unit
Dec. 31, 2014
USD ($)
Dec. 31, 2013
USD ($)
Summary Of Significant Accounting Policies [Line Items]        
Allowance for doubtful accounts   $ 0 $ 100,000  
Bed debt expense   0 100,000  
PV of short term receivable   46,849,000 0  
PV of long term receivable   45,573,000 0  
Inventory reserve   300,000 100,000  
Impairments related to intangible assets   $ 4,700,000 $ 0 $ 0
Number of segments | segment   1    
Number of reporting units | reporting_unit   1    
Number of reporting units reviewed as goodwill | reporting_unit   1    
Minimum        
Summary Of Significant Accounting Policies [Line Items]        
Assets useful life (in years)   1 year    
Maximum        
Summary Of Significant Accounting Policies [Line Items]        
Assets useful life (in years)   16 years    
Suppliers        
Summary Of Significant Accounting Policies [Line Items]        
Concentration percentage   33.00%    
Chenodal | Suppliers        
Summary Of Significant Accounting Policies [Line Items]        
Concentration percentage   4.00%    
Thiola | Suppliers        
Summary Of Significant Accounting Policies [Line Items]        
Concentration percentage   63.00%    
Asset Purchase Agreement | Asklepion Pharmaceuticals LLC        
Summary Of Significant Accounting Policies [Line Items]        
Proceeds from sale of assets $ 245,000,000      
Discount rate of receivables 2.80%      
At Time Of Closing | Asset Purchase Agreement        
Summary Of Significant Accounting Policies [Line Items]        
PV of short term and long term receivables $ 46,200,000      
At Time Of Closing | Asset Purchase Agreement | Asklepion Pharmaceuticals LLC        
Summary Of Significant Accounting Policies [Line Items]        
Proceeds from sale of assets 150,000,000      
Due On First And Second Anniversaries Of Closing | Asset Purchase Agreement        
Summary Of Significant Accounting Policies [Line Items]        
PV of short term and long term receivables 44,900,000      
Due On First And Second Anniversaries Of Closing | Asset Purchase Agreement | Asklepion Pharmaceuticals LLC        
Summary Of Significant Accounting Policies [Line Items]        
Proceeds from sale of assets $ 47,500,000      
Interest expense, net | Asset Purchase Agreement | Asklepion Pharmaceuticals LLC        
Summary Of Significant Accounting Policies [Line Items]        
Accretion on the notes receivable   $ 1,300,000